Safety of Celecoxib in Patients With Crohn's Disease
Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The investigators will select 60 people who are 18-70 years of age with Crohn's disease and
randomly assign them to receive an 8-week trial of celecoxib and an 8-week trial of a
placebo. There will be a 1-week interval or "wash-out" between trials when the participant
does not take any study medication. The investigators will monitor the participants for 18
weeks after they start the medication and observe their Crohn's disease activity, assessing
for flare-ups or exacerbations in the disease and other possible side effects of celecoxib.
Based on these observations, a determination will be made by the investigators as to the
safety of celecoxib. If celecoxib is found to be safe, then it may provide physicians with a
medication that they can prescribe for people who have Crohn's disease and experience chronic
pain from arthritis and arthralgia.